NCT05656209View on ClinicalTrials.gov

LA Improves the Prognosis of Patients With ICVD After Surgery

NANot yet recruitingINTERVENTIONAL

Enrollment

236

Participants

Timeline

Start Date

December 18, 2022

Primary Completion Date

December 18, 2022

Study Completion Date

December 31, 2027

Conditions

Ischemia; CerebrovascularCognitive Impairment

Interventions

DIETARY_SUPPLEMENT

Lactobacillus acidophilus

Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.

All Listed Sponsors

lead

Huaqiu Zhang

OTHER

NCT05656209 - LA Improves the Prognosis of Patients With ICVD After Surgery | Biotech Hunter | Biotech Hunter